SOURCE: BioMedReports


June 23, 2010 08:00 ET

Hythiam CEO Feeling Confident About Company's Progress and Immediate Future

LOS ANGELES, CA--(Marketwire - June 23, 2010) - BioMedReports, the news portal which first reported the persistent rumors about new contracts between major health plan providers and Hythiam Inc. (OTCBB: HYTM), is confirming that the company may finally be on the verge of announcing significant contracts -- a major step which has eluded the publicly traded small-cap company for some time.

According to analysts, a contract with a major health plan provider would not only support, but also validate Hythiam's innovative (some say controversial), proprietary and integrated substance dependence treatment program, that combines medical interventions, psychosocial therapy and care coaching that many see as a less expensive and effective treatment option.

In an exclusive interview which appears at BioMedReports.Com today, Terren S. Peizer, CEO of Hythiam, says: "We are in the right place, at the right time, we finally have the goods and we have all these tailwinds at our back with health plans across the country to come up with a solution and we have the only integrated solution, the only easily plug and play solution, the only one that they can adopt in the next year. It's exciting. It's been a long road. It's been a very bumpy road, mostly down over the last 2 years, but I think we're on our way now."

According to the special report, when health plans look at the cost of addiction, they look at how much of the behavioral health dollars are being spent on addiction. Unfortunately they find that only 6% of the costs show up on treatments while 94% of the costs show up on the medical side, in terms of emergency room visits, readmittance, etc. Hythiam has positioned itself to change those economic dynamics and the industry is apparently taking notice.

The complete analysis of the company appears today at BioMedReports.Com.

Biotech investors interested in accessing the news portal's exclusive trade alerts as well as their database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com

BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556